Dexela Announces the appointment of leading industry experts to its Board

Dexela Limited ("Dexela"), a leader in the development of accurate and sensitive 3-D breast imaging methods for the early detection of breast cancer, announces the creation of its new Board of Directors. Professor Sir Michael Brady FRS FREng has been appointed Non-Executive Chairman with Dr. Ronald B. Schilling and Michael Penington joining him as Non-Executive Directors, and Dr. Edward Bullard (CEO) and Dr. Marty Stanton as Executive Directors.

Professor Brady is currently BP professor of Information Engineering at the University of Oxford, where he has established the Robotics Research Laboratory and the Medical Vision Laboratory. The latter has a focus on medical image analysis and minimally invasive surgery. He is a fellow of a number of engineering and scientific bodies including the Royal Society and the Royal Academy of Engineers as well as honorary professor at several other universities. In 2000 he was awarded the Faraday Medal and the Third Millennium Medal of the IEEE.

Professor Brady is a Non-Executive Director of a number of companies in the medical and engineering sector, including Oxford Instruments where he is Deputy Chairman (one of the UK's leading scientific instruments companies, Ixico (a start up business aiming to provide software solutions for the pharmaceutical industry), and ISIS Innovation (Oxford University's intellectual property company). He co-founded Mirada, a medical imaging software company, which was sold to CTI for $23m in 2003 and has now become Siemens Molecular Imaging Advanced Applications.

Also joining the Board is Dr. Ronald B Schilling. Dr. Schilling brings to the Board 35 years of operating and general management experience in the medical device and technology industries. He was formerly Senior Vice President and General Manager of Toshiba America Medical Systems and before that was President of Diasonics MRI and General Manager at GE Medical Systems USA. Dr. Schilling has a Ph.D. in Electrical Engineering and is a fellow of the American Institute for Medical and Biological Engineering.

A third appointment to the Board is Michael Penington. Michael is Non-Executive Director of a number of growing technology companies in the UK as well as Chairman of WEP (Warwick Effect Polymers). He is also a senior independent Non-Executive Director of Future Publishing plc. Michael has a background in investment banking and corporate finance and holds a D.Phil. in Mathematics from the University of Oxford.

Executive Directors of Dexela’s newly formed Board include Managing Director and CEO Dr. Edward Bullard and Dr. Marty Stanton, President and Head of Research and Development. Prior to Co-founding Dexela in 2005, Dr. Bullard founded and directed a highly successful London-based software and IT consulting company. Dr. Stanton joins Dexela after having founded Archemix – an emerging biopharmaceutical located in Cambridge, Massachusetts. Prior to that, Marty led a research group at Brandeis University that originally developed the 3D breast imaging methods now being commercialized by Dexela.

Dr. Ed Bullard commented on the appointments: "I am delighted to announce the new Board of Dexela. We are honoured to have so many highly experienced and talented individuals on our Board. Our Non-Executive Directors Michael Brady, Michael Penington and Ron Schilling bring with them a wealth of understanding that will help us in all areas of developing the business. They each have diverse and impressive backgrounds in engineering and supporting small business that lead significant technological advances. We now believe that we have the team at Dexela to enable a revolution in breast cancer diagnosis".

Brady added: "I am delighted to be joining the Board of such a significant growing company with such important technological IP. Dexela is leading the way in tomosynthesis, which in my opinion will prove to be one of the major developments in breast imaging".



For more information please visit www.dexelaimaging.com or contact:

Edward Bullard
CEO Dexela Limited
Tel: 07980 210 710
Email: edward@dexelaimaging.com

Notes to Editors

Formed in 2005 to address significant unmet medical need in the early detection of breast cancer, Dexela is developing innovative, low-radiation breast screening techniques that not only may extend the benefits of breast cancer screening to women under fifty, but may also reduce call backs due to false positive results and increase the sensitivity of breast cancer detection, leading to fewer cancers being missed by doctors.

Dexela has a talented and experienced team of award-winning scientists, as well as a strong portfolio of intellectual property and it is this team which has developed world-leading technology for the acquisition, processing and visualisation of high resolution 3-D images of the breast, a type of imaging known as Tomosynthesis. Dexela’s novel approach to Tomosynthesis has significant clinical advantages over competing approaches. They now intend to use this position to secure the leading role in the field and establish collaborative agreements with medical device manufacturers.